Business, energy, technology, markets and global industry news from Business News Today

Halozyme Therapeutics

PharmaDeviceNews Halozyme Therapeutics
Natera’s Signatera blood-based MRD test showed higher sensitivity than AMERK in predicting Merkel cell carcinoma recurrence, according to a JAMA Dermatology study. Representative image.
Pharma & Biotech

Rybrevant Faspro shrank tumours in 42% of heavily treated head and neck cancer patients. Can Phase 3 confirm the benefit?

FDA grants Rybrevant Faspro accelerated approval in advanced head and neck cancer after a 42% response rate, with Phase 3 confirmation still required.

Read More
Johnson & Johnson targets second-line head and neck cancer treatment with amivantamab
Pharma & Biotech

Rybrevant Faspro shrank tumours in 42% of patients, but can Johnson & Johnson prove survival benefit?

FDA approves Rybrevant Faspro for selected advanced head and neck cancers after a 42% response rate. Survival evidence remains the next test.

Read More
Representative image of Alzheimer's disease research and brain imaging as Acumen Pharmaceuticals discontinues its experimental drug sabirnetug (ACU193) after the Phase 2 ALTITUDE-AD trial fails to slow cognitive decline despite significant amyloid plaque reduction.
Features & Analysis

Sabirnetug trial failure forces Acumen Pharmaceuticals to reassess Alzheimer’s drug development strategy

Acumen Pharmaceuticals halts sabirnetug after its Phase 2 Alzheimer's trial fails despite amyloid reduction. Discover what the findings mean.

Read More
Pharma & Biotech

Johnson & Johnson strengthens its multiple myeloma franchise with TECVAYLI and DARZALEX FASPRO approval. What clinicians are watching next

FDA approves TECVAYLI plus DARZALEX FASPRO for relapsed multiple myeloma. Discover what the MajesTEC-3 data means for future immunotherapy strategies.

Read More